efzofitimod

Home
Ligands
efzofitimod

GtoPdb Ligand ID: 13199

Synonyms: ATYR-1923 | ATYR1923 | KRP-R120

Compound class: Peptide or derivative

Comment: Efzofitimod (ATYR1923) is a Fc fusion protein [1]. The C-terminal 59 amino acids corresponds to the active N-terminal domain of histidyl-tRNA synthetase (HARS), an extracellular non-catalytic isoform that is upregulated by inflammatory cytokine stimulation in the lung. The IgG1 Fc domain extends the peptide's circulating half-life. The HARS domain binds selectively to the cell surface receptor neuropilin 2 (NRP2; O60462, which is an immunomodulatory protein and molecular target for inflammatory diseases [5]. In the airways, NRP2 plays an important role in activation of myeloid cells and their recruitment to inflammatory sites [3]. Efzofitimod was developed as a clinical candidate immunotherpy with potential for immune-mediated fibrotic lung conditions.

Immunopharmacology Comments
Efzofitimod targets NRP2 which is upregulated on immune cells in response to lung inflammation. Functionally, efzofitimod is proposed to downregulate the innate and adaptive immune responses in dysregulated inflammatory disease states. It is being evaluated a mechanism to reduce the accumulation of immune cells in lung tissue that acts as a driver of pathology in chronic inflammatory lung conditions such as pulmonary sarcoidosis and interstitial lung disease (ILD).

Immunopharmacology Comments

Efzofitimod targets NRP2 which is upregulated on immune cells in response to lung inflammation. Functionally, efzofitimod is proposed to downregulate the innate and adaptive immune responses in dysregulated inflammatory disease states. It is being evaluated a mechanism to reduce the accumulation of immune cells in lung tissue that acts as a driver of pathology in chronic inflammatory lung conditions such as pulmonary sarcoidosis and interstitial lung disease (ILD).